Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SMO


Brief Information

Name:Smoothened receptor
Target Synonym:SMO,SMOH,Smoothened, Frizzled Class Receptor,Smoothened, Frizzled Family Receptor,Frizzled Family Member 11,Protein Gx,Seven Transmembrane Helix Receptor,Smoothened Homolog (Drosophila),Smoothened Homolog,FZD11,CRJS,Gx,Smoothened Receptor,Smoothened, Seven Transmembrane Spanning Receptor,Smoothened (Drosophila) Homolog
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SMO-H52P3 Human Human SMO Full Length Protein (VLP)
ACRO Quality

Part of Bioactivity data


Immobilized Human SMO Full Length Protein-VLP (Cat. No. SMO-H52P3) at 10 μg/mL (100 μL/well) can bind Anti-SMO antibody with a linear range of 0.01-2.5 μg/mL (QC tested).

Synonym Name

SMO,smoothened, frizzled class receptor,CRJS, FZD11, Gx, PHLS, SMOH


Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Glasdegib PF-04; PF-4449913; PF-04449913 Approved Pfizer Pharmaceuticals Ltd (China) Daurismo United States Leukemia, Myeloid, Acute Pfizer Europe Ma Eeig 2018-11-21 Solid tumours; Hematologic Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Kidney Diseases; Graft vs Host Disease; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Fasciitis Details
Vismodegib R-3616; RG-3616; GDC-0449 Approved Genentech Inc, F. Hoffmann-La Roche Ltd Erivedge United States Carcinoma, Basal Cell Roche Registration Gmbh 2012-01-30 Gliosarcoma; Liposarcoma; Chondrosarcoma, Clear Cell; Multiple Myeloma; Neurofibrosarcoma; Sarcoma; Osteosarcoma; Sarcoma, Ewing; Breast Neoplasms; Prostatic Neoplasms; Brain Neoplasms; Basal Cell Nevus Syndrome; Colorectal Neoplasms; Sarcoma, Synovial; Gastrointestinal Stromal Tumors; Uterine Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Pancreatic Ductal; Chondrosarcoma, Mesenchymal; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma, Kaposi; Neuroectodermal Tumors, Primitive, Peripheral; Hemangioendothelioma, Epithelioid; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Stomach Neoplasms; Rhabdomyosarcoma; Solid tumours; Medulloblastoma; Ovarian Neoplasms; Fibrosarcoma; Chondrosarcoma; Desmoplastic Small Round Cell Tumor; Hemangiosarcoma; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Mesenchymoma; Esophageal Neoplasms; Leiomyosarcoma; Ganglioglioma; Neoplasms; Pancreatic Neoplasms; Dermatofibrosarcoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Glioblastoma; Graft vs Host Disease; Skin Neo Details
Sonidegib Diphosphate LDE-225; NVP-LDE-225 Approved Novartis Pharma Ag Odomzo, 奥昔朵 United States Carcinoma, Basal Cell Shanghai Jiyu Pharmaceutical Technology Co Ltd 2015-07-24 Primary Myelofibrosis; Graft vs Host Disease; Fibrosis; Skin Neoplasms; Multiple Myeloma; Thrombocytosis; Prostatic Neoplasms; Breast Neoplasms; Basal Cell Nevus Syndrome; Neuroblastoma; Bone Marrow Diseases; Glioblastoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Leukemia, Myeloid, Acute; Glioma; Thrombocythemia, Essential; Adenocarcinoma; Carcinoma, Hepatocellular; Esophageal Neoplasms; Ovarian Neoplasms; Blood Coagulation Disorders; Bone Marrow Neoplasms; Hematologic Diseases; Hemorrhagic Disorders; Solid tumours; Leukemia, Myelogenous, Chronic; Leukemia; Rhabdomyosarcoma; Hematologic Neoplasms; Medulloblastoma; Polycythemia Vera; Carcinoma, Basal Cell; Hepatoblastoma; Stomach Neoplasms; Blood Platelet Disorders; Myeloproliferative Disorders; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Triple Negative Breast Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ZSP-1602 ZSP-1602 Phase 1 Clinical Guangdong Zhongsheng Pharmaceutical Co Ltd Medulloblastoma; Carcinoma, Basal Cell; Carcinoma; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Glioma; Adenocarcinoma Details
Cipromedegib SHR-1539 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Medulloblastoma; Stomach Neoplasms; Carcinoma, Basal Cell; Lung Neoplasms Details
GT-1708F GT-1708F; GT-1708 Phase 1 Clinical Suzhou Kintor Pharmaceuticals Inc Hematologic Neoplasms; Solid tumours Details
Taladegib RXDX-109; ENV-IPF-101; ENV-ONC-101; LY-2940680; ENV-101 Phase 2 Clinical Eli Lilly And Company Solid tumours; Medulloblastoma; Rhabdomyosarcoma; Esophageal Neoplasms; Idiopathic Pulmonary Fibrosis; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Cholangiocarcinoma; Sarcoma; Breast Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis; Adenocarcinoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message